Framework Journal · one stock, one dated entry

Recorded 2026-05-22 · Permanent

Replimune Group, Inc. REPL

Outside both standards

An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.

The label
Markup

read at $9.47

Replimune Group, Inc. holds its Markup at $9.47.

PHINPOOPSC
  • PHPhase · the trend structure carries the Markup label
  • INInsiders · no filings inside 60 days, left as found
  • POPositioning · no disclosures inside 60 days, left as found
  • OPOptions · no verdict drawn today, left as found
  • SCScreen · does not pass the values gate
  • edge confirmed
  • edge broken
  • edge forming

Each arm is one independent read. Conviction is not a single call, it is how many edges converge.

The investor read · the season, not the day

As held on the ledger · 2026-05-22
PhaseMarkup
Quantitative stateConsolidating, no directional conviction, held for 8 days
Price$9.47
Valuation0.00 trailing · -2.35 forward price to earnings
Values screenFAIL
BetaN/A

The business, in plain words · what the numbers mean

The fundamentals · plain-English read
Forward P/E-2.3x
Trailing P/E0.0x
Revenue growth0.0%
revenue is shrinking
Profit margin0.0%
currently unprofitable
Return on equity-90.9%
not currently earning a positive return on equity
Debt to equity0.36
minimal debt — a conservative balance sheet
Market cap$403M

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & how to trade · wherever in the world you are

REPL trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The trader read · the latest dated commentary

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (6 analysts) rates it none, with a mean price target of $4. Entered 2026-07-18 · Markup

The dated journal · newest first, never edited

2026-07-18 Markup $9.47 +0.0% Entry 3

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (6 analysts) rates it none, with a mean price target of $4.

2026-07-03 Markup $9.47 +0.0% Entry 2

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.

2026-07-02 Markup $9.47 Entry 1

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

The insider ledger · Form 4 filings, as filed

Most recent filings · REPL
DateInsiderTitleTypeSharesValue
2026-05-18 SARCHI CHRISTOPHER Officer 8,626 $43,820
2026-05-18 ASTLEY-SPARKE PHILIP Director 17,657 $89,698
2026-05-18 HILL EMILY LUISA Chief Financial Officer 7,812 $39,685
2026-05-18 PATEL SUSHIL Chief Executive Officer 37,324 $189,606
2026-05-18 XYNOS KONSTANTINOS Officer 14,023 $71,237
2026-05-18 SCHWENDENMAN ANDREW Officer 7,894 $40,102
2026-04-02 SARCHI CHRISTOPHER Officer 6,500 $52,065
2026-04-01 ASTLEY-SPARKE PHILIP Director 50,000 ·
2026-04-01 HILL EMILY LUISA Chief Financial Officer 50,000 ·
2026-04-01 PATEL SUSHIL Chief Executive Officer 251,240 ·

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What holding actually paid · price plus dividends

If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $3.74 +126.9% · $2,269 +126.9%
2 months $4.76 +78.3% · $1,783 +78.3%
3 months $7.58 +11.9% · $1,119 +11.9%
6 months $9.87 -14.0% · $860 -14.0%
1 year $10.13 -16.2% · $838 -16.2%
2 years $9.00 -5.7% · $943 -5.7%
3 years $22.47 -62.2% · $378 -62.2%
5 years $34.00 -75.0% · $250 -75.0%

Historical returns from market close data. Past performance does not guarantee future results.

This entry now belongs to the ledger. Whatever REPL does next, these words stay.

Replimune Group, Inc. · REPL · Markup · $9.47
Recorded 2026-05-22 · before the outcome · scored mechanically

All of today's entries See the running score

Get our weekly market brief free.